Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI
Known for their low-dose therapeutic efficacy and high target affinity, high-potency active pharmaceutical ingredients (HPAPIs) are in high demand by biopharma companies, which often outsource their production.
Approximately 41% of innovator and biosimilar HPAPIs come from contract development and manufacturing organizations (CDMOs). With strategic acquisitions and expansions of HPAPI facilities reshaping the HPAPI outsourcing market, four CDMOs – Lonza (LONN: SIX), Siegfried, Aspen, and Veranova - are competing for leadership, with two of them, Lonza and Siegfried, pulling out in front, according to pharma intelligence firm GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze